


LISTING OF CLAIMS

What is claimed is:

1. (Currently Amended) A compound having the formula I



wherein

X<sup>1</sup>, X<sup>2</sup>, Y<sup>1</sup>, and Y<sup>2</sup> comprises, independently, hydrogen, fluorine, a hydroxyl group, a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, OR<sup>2</sup>, ~~OCCH<sub>2</sub>CH<sub>2</sub>OR<sup>3</sup>~~, OC(O)R<sup>3</sup>, or NC(O)R<sup>3</sup>;

each U comprises, independently, oxygen, sulfur, or NR<sup>1</sup>;

V is not present or when V is present, V comprises oxygen or sulfur;

W comprises oxygen or sulfur;

Z comprises oxygen, sulfur, NR<sup>1</sup>, CHF, CF<sub>2</sub>, or CHOR<sup>2</sup>;

each R<sup>1</sup> comprises, independently, hydrogen, a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, a cationic counterion, or both R<sup>1</sup> form a cyclic or heterocyclic group;

R<sup>2</sup> comprises hydrogen, a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group or a protecting group;

R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, a cycloalkyl group, a heterocycloalkyl group, an aryl group, a heteroaryl group,

or a pharmaceutically acceptable salt or ester thereof,

wherein when Y<sup>1</sup> and Y<sup>2</sup> are different groups, the stereochemistry at carbon a is either substantially R or substantially S, and

wherein the compound having the formula I is not 1-acyl-*sn*-glycerol 3-phosphate and 2-acyl-*sn*-glycerol 3-phosphate, and  
wherein when V is not present, W is oxygen, X<sup>1</sup> and Y<sup>1</sup> are hydrogen, and X<sup>2</sup> is hydroxyl, then Y<sup>2</sup> is not hydroxyl.

2. (Original) The compound of claim 1, wherein each U and W comprises oxygen and V is not present.
3. (Withdrawn) The compound of claim 2, wherein Z comprises oxygen, X<sup>1</sup> comprises hydrogen, and X<sup>2</sup> comprises fluorine.
4. (Withdrawn) The compound of claim 3, wherein Y<sup>1</sup> comprises hydrogen, Y<sup>2</sup> comprises OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, and R<sup>1</sup> comprises hydrogen.
5. (Canceled)
6. (Withdrawn) The compound of claim 2, wherein Z comprises oxygen, Y<sup>1</sup> comprises hydrogen, and Y<sup>2</sup> comprises fluorine.
7. (Withdrawn) The compound of claim 6, wherein X<sup>1</sup> comprises hydrogen, X<sup>2</sup> comprises OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, and each R<sup>1</sup> comprises hydrogen.
8. (Original) The compound of claim 2, wherein Z comprises CHF, Y<sup>1</sup> comprises hydrogen, and Y<sup>2</sup> comprises a hydroxyl group.
9. (Withdrawn) The compound of claim 8, wherein X<sup>1</sup> comprises hydrogen, X<sup>2</sup> comprises OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, and each R<sup>1</sup> is hydrogen.
10. (Canceled)
11. (Withdrawn) The compound of claim 8, wherein X<sup>1</sup> comprises hydrogen, X<sup>2</sup> is OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, and each R<sup>1</sup> comprises ethyl.
12. (Canceled)

ATTORNEY DOCKET NO. 24U03.1-071  
PATENT

13. (Withdrawn) The compound of claim 2, wherein Z comprises CHF, Y<sup>1</sup> comprises hydrogen, and Y<sup>2</sup> comprises an alkyl group.
14. (Withdrawn) The compound of claim 13, wherein X<sup>1</sup> comprises hydrogen, X<sup>2</sup> comprises a silyl group, a hydroxyl group, or OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, and each R<sup>1</sup> comprises ethyl or each R<sup>1</sup> comprises hydrogen.
15. (Withdrawn) The compound of claim 2, wherein Z comprises CHF, Y<sup>1</sup> comprises hydrogen, and Y<sup>2</sup> comprises an OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group.
16. (Canceled)
17. (Withdrawn) The compound of claim 2, wherein Z comprises CF<sub>2</sub>.
18. (Withdrawn) The compound of claim 17, wherein Y<sup>1</sup> comprises hydrogen, Y<sup>2</sup> comprises OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, and each R<sup>1</sup> comprises an ethyl group or a sodium ion.
19. (Withdrawn) The compound of claim 18, wherein X<sup>1</sup> comprises hydrogen and X<sup>2</sup> comprises OH or OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group.
20. (Withdrawn) The compound of claim 17, wherein X<sup>1</sup> comprises hydrogen, X<sup>2</sup> is OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group, and each R<sup>1</sup> comprises an ethyl group or a sodium ion.
21. (Withdrawn) The compound of claim 20, wherein Y<sup>1</sup> comprises hydrogen and Y<sup>2</sup> comprises OH or OC(O)R<sup>3</sup>, wherein R<sup>3</sup> comprises a branched or straight chain C<sub>1</sub> to C<sub>25</sub> alkyl group.

Claims 22-72 Cancelled

73. (Withdrawn-previously presented) A method for improving wound healing in a subject in need of such improvement, comprising contacting the wound of a mammal with a compound of claim 1.

- 74. (Withdrawn-previously presented) A method for treating or preventing in a subject a disease comprising administering to the subject a compound of claim 1.
- 75. (Withdrawn) The method of claim 74, wherein the disease comprises cancer or diabetes.
- 76. (Canceled)
- 77. (Withdrawn-previously presented) A method for reducing inflammation or an allergic response in a subject comprising administering to the subject a compound of claim 1.
- 78. (Withdrawn-previously presented) A method for increasing or altering cardiovascular function in a subject comprising administering to the subject a compound of claim 1.
- 79. (Withdrawn-previously presented) A method for maintaining or terminating embryonic development in a subject comprising administering to the subject a compound of claim 1.
- 80. (Withdrawn-previously presented) A method for eliciting or inhibiting platelet aggregation in a subject comprising administering to the subject a compound of claim 1.
- 81. (Withdrawn-previously presented) A method for increasing or inhibiting cell growth and proliferation in a culture comprising contacting the cells in the culture with a compound of claim 1.
- 82. (Withdrawn-previously presented) A method of treating or preventing a disease in a subject comprising administering a compound of claim 1 thereof as a PPAR $\gamma$  agonist.
- 83. (Withdrawn-previously presented) A method of treating or preventing a disease in a subject comprising administering a compound of claim 1 to inhibit a lipid phosphatase, lipid kinase, or phospholipase enzyme.
- 84. (Withdrawn-previously presented) The use of a compound of claim 1 for targeting the discovery of a drug.

**ATTORNEY DOCKET NO. 24U03.1-071**  
**PATENT**

- 85. (Withdrawn-previously presented) A method for growing or proliferating cells in a culture comprising administering to the cells in the culture a compound of claim 1.
- 86. (Withdrawn-previously presented) A method for determining the activity of lysophosphatidic acid or phosphatidic acid, comprising the steps of:
  - a) measuring the activity of a compound of claim 1; and
  - b) measuring the same activity of lysophosphatidic acid or phosphatidic acid.
- 87. (Withdrawn) The method of claim 86, wherein the method comprises identifying agonists or antagonists of lysophosphatidic acid binding to or activating lysophosphatidic acid receptors of the edg class in a cell.
- 88. (Withdrawn) The method of claim 86, wherein the method comprises identifying agonists or antagonists of lysophosphatidic acid binding to or activating lysophosphatidic acid receptors of the non-edg class in a cell.